The performance of interferon-gamma release assay in nontuberculous mycobacterial diseases: a retrospective study in China

Mao-Shui Wang¹, Jun-Li Wang*² and Xin-Feng Wang¹*

Abstract

Background: The interferon-gamma release assay (IGRA) is more specific than the tuberculin skin test to discriminate between tuberculosis (TB) and nontuberculous mycobacterial (NTM) diseases. Here we performed a retrospective study to evaluate the performance of the T-SPOT.TB in patients with NTM diseases.

Methods: Between March, 2013 and Nov, 2015, a total of 58 patients with NTM diseases had a T-SPOT.TB performed were enrolled, 30 patients had definite NTM diseases, 28 had probable diseases. Their clinicopathological characteristics were reviewed and analyzed. Cultures for mycobacteria were performed. The indirect proportion method with Löwenstein–Jensen (L-J) medium was used for first-line drug susceptibility test. T-SPOT.TB assay was performed according to the manufacturer’s instructions. Data were expressed as mean ± standard deviation (continuous variables) and as numbers and percentages (categorical variables). The χ² test was used for comparisons between proportions.

Results: The average age was 51.8 ± 16.1 years (range 10 to 77 years), 58.6% (34/58) were male. 16.4% (9/55) were TB-PCR positive. 34 (58.6%) isolates were Mycobacterium intracellulare, ten (17.2%) were Mycobacterium chelonae and seven (12.1%) were Mycobacterium fortuitum. Fifty-two (89.7%) patients were NTM lung disease, five (8.6%) were pleural disease, and one (1.7%) lymphadenitis. The total positivity of T-SPOT.TB was 53.4% (31/58) among the whole group (probable and definite). For probable cases, the T-SPOT.TB assay was positive in 53.5% (15/28); for definite cases, 16 (53.3%) of 30 definite cases were positive. There was no statistical difference in the positivity rate between them (P < 0.01).

Conclusions: In the study, we showed that a significant portion of NTM diseases were T-SPOT.TB positive in China. Although T-SPOT.TB is useful diagnostic method for differentiating TB from NTM diseases, in China, the IGRA assay show limited value in the discrimination. In addition, further research is needed to investigate the association between TB infection and treatment for NTM patients.

Keywords: T-SPOT.TB, Nontuberculous mycobacterium infections, Tuberculosis, Mixed infection
Background
The nontuberculous mycobacteria (NTM) are ubiquitous microorganisms found in various environments [1]. NTM can cause both asymptomatic infection and symptomatic disease, lung is the most common site of NTM infection. It is noteworthy that the prevalence of NTM disease is increasingly reported worldwide [2]. In China, the most frequent causative organisms of NTM are Mycobacterium intracellulare (81.2%), Mycobacterium kansasii (7.8%) and Mycobacterium fortuitum (4.7%) [3].

Currently, the lack of randomized clinical trials to guide treatment results in that treatment strategies are largely based on expert opinion [4, 5]. Meanwhile, the diagnosis of pulmonary NTM disease is significantly delayed in China [6]. NTM diseases share clinical signs with tuberculosis (TB), causing a clinical dilemma in differentiation between NTM infection and TB. Until now, the Tuberculin skin test (TST) remains to be used for detecting latent TB infection and an adjunctive test for the Tuberculin skin test (TST). The goal of this retrospective study is to evaluate the performance of the T-SPOT.TB assay in patients with NTM diseases in a high TB-burden country.

Results
Table 1 shows the characteristics of the participants of this study. The average age was 51.8 ± 16.1 years (range 10 to 77 years), 58.6% (34/58) were male. One hundred percent (51/51) were HIV-negative. 50.9% (29/57) were positive for acid-fast bacillus staining. NTM were cultured from sputum (84.5%), pleural effusion (8.6%), bronchial brushing (5.2%) and tissues (1.7%). Thirty-four (58.6%) isolates were Mycobacterium intracellulare, ten (17.2%) were Mycobacterium chelonae, seven (12.1%) were Mycobacterium fortuitum, four (6.9%) were Mycobacterium kansasii, one (1.7%) were Mycobacterium avium, one (1.7%) were Mycobacterium scrofulaceum and one (1.7%) were Mycobacterium terrae. Phenotypic DST was performed on 49 isolates, 48 (98.0%) isolates were resistant to isoniazid, 44 (89.8%) resistant to rifampin, 43 (87.8%) resistant to streptomycin, 26 (53.1%) resistant to ethambutol and 24 (49.0%) resistant to the four drugs.
Fifty-two (89.7%) patients were NTM lung disease, five (8.6%) were pleural disease, and one (1.7%) lymphadenitis. Thirty-seven (63.8%) patients had cough, 24 (41.4%) fever, 18 (31.0%) dyspnea and five (8.6%) hemoptysis. Eight (13.8%) patients were asymptomatic and admitted for abnormality of chest X-ray. Seven patients have contact history with a TB patient in the family.

The total positivity of T-SPOT.TB was 53.4% (31/58) among the NTM group (probable and definite). For probable cases, the T-SPOT.TB assay was positive in 53.5% (15/28); for definite cases, 16 (53.3%) of 30 definite cases were positive; there was no statistical difference in the positivity rate between them (P < 0.01). For NTM strains, 47.1% (16/34) of Mycobacterium intracellulare cases were positive on T-SPOT.TB assay (seven were probable, nine definite); 70% (7/10) of Mycobacterium chelonae cases were T-SPOT.TB positive (three were probable, four definite); 57.1% (4/7) of Mycobacterium fortuitum cases were T-SPOT.TB positive (all were definite).

### Table 1 Demographic and clinical characteristics of probable and definite NTM patients

|                      | Probable (n = 28) | Definite (n = 30) | Total (n = 58) |
|----------------------|------------------|------------------|---------------|
| Age (years)          | 55.8 ± 13.1      | 48.0 ± 17.9      | 51.8 ± 16.1   |
| Sex, male            | 53.5% (15)       | 63.3% (19)       | 58.6% (34/58) |
| HIV (+)              | 100% (25/25)     | 100% (26/26)     | 100% (51/51)  |
| TB-PCR (+)           | 10.7% (3/28)     | 22.2% (6/27)     | 16.4% (9/55)  |
| AFB staining (+)     | 63.0% (17/27)    | 40% (12/30)      | 50.9% (29/57) |
| NTM strains          |                  |                  |               |
| Mycobacterium intra-| 60.7% (17)       | 56.7% (17)       | 58.6% (34/58) |
| cellulare            |                  |                  |               |
| Mycobacterium chel- | 17.9% (5)        | 16.7% (5)        | 17.2% (10/58) |
| onae                 |                  |                  |               |
| Mycobacterium for-  | 10.7% (3)        | 13.3% (4)        | 12.1% (7/58)  |
| tuitum               |                  |                  |               |
| Mycobacterium kansas| 10.7% (3)        | 3.3% (1)         | 6.9% (4/58)   |
| avium                | 0                | 3.3% (1)         | 1.7% (1/58)   |
| M. terrae            | 0                | 3.3% (1)         | 1.7% (1/58)   |
| M. scrofulaceum      | 0                | 3.3% (1)         | 1.7% (1/58)   |
| DST (resistance)     |                  |                  |               |
| Isoniazid (1 μg/ml)  | 95.2% (20/21)    | 100% (28/28)     | 98.0% (48/49) |
| Rifampin (50 μg/ml)  | 85.7% (18/21)    | 92.9% (26/28)    | 89.8% (44/49) |
| Streptomycin (10 μg/| 90.5% (19/21)    | 85.7% (24/28)    | 87.8% (43/49) |
| ml)                  |                  |                  |               |
| Ethambutol (5 μg/ml) | 47.6% (10/21)    | 57.1% (16/28)    | 53.1% (26/49) |
| First-line drugs     | 42.9% (9/21)     | 53.5% (15/28)    | 49.0% (24/49) |
| Symptoms             |                  |                  |               |
| Cough                | 67.9% (19)       | 60.0% (18)       | 63.8% (37)    |
| Fever                | 53.6% (15)       | 30.0% (9)        | 41.4% (24)    |
| Dyspnea              | 25.0% (7)        | 36.7% (11)       | 31.0% (18)    |
| Hemoptysis           | 7.1% (2)         | 10.0% (3)        | 8.6% (5)      |
| T-SPOT.TB (+)        | 53.5% (15/28)    | 53.3% (16/30)    | 53.4% (31/58) |

**Discussion**

China, as one of the 22 high TB-burden countries, *M. TB* remains to be the main cause of pulmonary mycobacteria diseases. Differentiation between NTM infection and TB is very difficult. Since IGRAs has the potential to differentiate TB from NTM diseases, we aimed to evaluate the use of T-SPOT.TB for the discrimination in China. Surprisingly, in the study, a high proportion of NTM patients were found to be T-SPOT.TB positive. The result implied that, 1) TB infection among NTM diseases was common in China; 2) T-SPOT.TB have limited value in discrimination of NTM diseases and TB in China, so the diagnosis of NTM diseases remains to rely on routine methods (such as culture). To best of our knowledge, this is the first report for evaluating the performance of IGRAs in NTM disease in the high TB-burden country.

It was previously thought that each patient get one kind of diseases (NTM or TB). Nonetheless, the development of immunological and molecular methods
has led to increasing reports of mixed infection. Recently, several studies have reported the occurrence of mixed infection of TB and NTM [19–22]. In the study, we also found that 53.4% patients were T-SPOT.TB positive, and 16.4% NTM patients were TB-PCR positive. However, a study conducted at our hospital showed that, in the health care workers, the overall positivity rate of T-SPOT.TB test was 13.9% (122 out of 879; 95% CI 11.7–16.3%) [23]. Moreover, in a positive control group, including 238 culture confirmed TB patients (aged 39.1 ± 19.5, 64.7% were male), the positivity of T-SPOT.TB was 86.1% (205/238), our further statistical analysis showed the positivity of T-SPOT.TB in NTM diseases is lower than in positive control (data not published). Therefore, our findings should be a direct proof for the mixed infection. The coexistence of TB and NTM has very important clinical significance in some patients, mixed infection may be one of the reasons that may lead to failure in therapy of NTM diseases, so caution should be exercised [21]. For example, there were five patients (8.6%) were retreatment NTM disease in our study. Usually, NTM isolates were resistant to the first-line anti-TB drug. Therefore, these drugs wouldn’t be the first choice for treatment of TB patients. But now, since the co-infection exists, these drugs sensitive for TB but resistant for NTM strains should be reconsidered. Moreover, an inaccurate diagnosis of NTM diseases can be made due to the presence of NTM, which sometimes leads to inappropriate treatment [21, 24]. In addition, mixed TB and NTM may also present clinical problems for culture and DST, such as failure to recognize TB, over-estimation severity of drug resistance.

Kendall et al. reported that a significant portion of pulmonary TB patients were identified to have NTM, particularly in patients with cavitation and those born in the US [25]. Another US study identified 11.0% of pulmonary TB patients with NTM species [26]. Simultaneous detection of *M. TB* and NTM in a specimen is possible because NTM may be present as colonizers or as pathogens and because NTM is ubiquitous in the environment and is isolated frequently in immunocompromised patients, such as HIV-infected individuals and patients on immunosuppressive treatment (for example, Anti-TNF drugs, corticosteroids) [27]. Thus, an analysis was performed by Hwang SM et al., it was reported that a significant portion of NTM patients were identified to have TB, ten patients (14.5%) had a history of TB, mixed cultures (NTM and *M. TB*) were present repeatedly in 12 patients (17.4%) [21]. This research should be the first report addressing the issues on mixed infection of TB and NTM.

For evaluating diagnostic role of IGRAs in discrimination of TB and NTM diseases, several studies have been performed in low TB-burden countries, it showed that the IGRAs hold potential to discriminate between NTM and TB infections. A Japanese study showed that QFT-GT had a mean sensitivity of 86% and a mean specificity of 94%, the test is a useful diagnostic method for differentiating between them [28]. Hermansen TS et al. found that QFT-GT was positive in 8% of patients with definite NTM disease, and in 4% of patients with definite disease infected with NTM without the RD1 region. [17]. But in our study, we found that a significant portion of NTM diseases were T-SPOT.TB positive in China. Similar result was reported in [14], but the author didn’t address the issue and contribute it to the cross-reactivity. It means that in China, the IGRA assay show limited value in the discrimination between TB and NTM diseases. In our study, six kinds of NTMs (*Mycobacterium intracellulare, Mycobacterium chelonae, Mycobacterium fortuitum, Mycobacterium kansasii, Mycobacterium avium* and *Mycobacterium terrae*) were isolated, only *Mycobacterium kansasii* was known to express ESAT-6 and CFP-10 [29].

Our study has some limitations that could have an impact on the results. Bias is more common in retrospective study. However, bias in this study was minimized by consecutive cases were enrolled, and patients have equal chance to participate in the study. The sample size was small, caution needed when interpreting the results. Finally current diagnostic methods couldn’t identify true active TB from these T-SPOT.TB or TB-PCR positive cases. Therefore, we have no further suggestion on how to choose appropriate regime for NTM cases with T-SPOT.TB or TB-PCR positive, but we think the first-line anti-TB drugs should be considered.

**Conclusions**

In the study, we showed that a significant portion of NTM diseases were T-SPOT.TB positive in China. Although T-SPOT.TB was useful diagnostic method for differentiating TB from NTM diseases in low-TB burden countries, in China, the IGRA assay show limited value in the discrimination. In addition, further research is needed to investigate the association between TB infection and treatment for NTM diseases.

**Abbreviations**

- DST: Drug susceptibility test; IGRA: Interferon-gamma release assay; NTM: Nontuberculous mycobacteria; QFT-GT: QuantiFERON-TB gold test; RD: Region of difference; TB: Tuberculosis; TB-PCR: Tuberculosis-polymerase chain reaction; TNF: Tumor necrosis factor; TST: Tuberculin skin test

**Acknowledgments**

We thank the medical doctors and nurses of the Shandong Provincial Chest Hospital for their assistance in participant inclusion and data collection, especially the members of our department.

**Funding**

This work was supported in part by a grant from the Science and Technology Department of Baise (NO.0908007); in part by a grant from the Science and Technology Department of Jinan (NO.201303043).
Availability of data and materials
The data analyzed in this study can be accessed by sending a request to the corresponding author.

Authors’ contributions
WJL and WXF conceived and designed the study, interpreted the analysis and contributed to writing the manuscript. WMS conducted the study, collected the data and contributed to data management analysis and interpretation. All authors have read and approved the final version of the manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
The Ethical Committee of Shandong Provincial Chest Hospital approved this study without the need to obtain informed consent.

Received: 29 June 2016 Accepted: 13 November 2016

Published online: 25 November 2016

References
1. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175:367–416.
2. Kendall BA, Winthrop KL. Update on the epidemiology of pulmonary nontuberculous mycobacterial infections. Semin Respir Crit Care Med. 2013;34:87–94.
3. Jing H, Wang H, Wang Y, Deng Y, Li X, Liu Z, et al. Prevalence of nontuberculous mycobacteriosis in China, 2004–2009. Emerg Infect Dis. 2012;18:527–8.
4. Novosad S, Henké E, Winthrop KL. The challenge of pulmonary nontuberculous mycobacterial infection. Curr Pulmonol Rep. 2015;4:152–61.
5. Kang YA, Koh WJ. Antibiotic treatment for nontuberculous mycobacterial lung disease. Expert Rev Respir Med. 2016;10:357–68.
6. Jing H, Tan W, Deng Y, Gao D, Li L, Lu Z, et al. Diagnostic delay of pulmonary nontuberculous mycobacterial infection in China. Multidiscip Respir Med. 2014;9:48.
7. Huebner RE, Schein MF, Bass Jr JB. The tuberculin skin test. Clin Infect Dis. 1993;17:968–75.
8. van Ingen J, de Zwaan R, Delhuijzen R, Boeree M, van Sooelingen D. Region of difference 1 in nontuberculous Mycobacterium species adds a phylogenetic and taxonomical character. J Bacteriol. 2009;191:5865–7.
9. Diel R, Goffelet D, Ferrara G, Bothmarley C, Girillo D, Kampmann B, et al. Interferon-gamma release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J. 2011;37:100–11.
10. van Ingen J, Rahim Z, Mulder A, Boeree MJ, Simeone R, Brosch R, et al. Characterization of Mycobacterium orygis as M. tuberculosis complex subspecies. Emerg Infect Dis. 2012;18:653–5.
11. Mahairas GG, Sabo PJ, Hickey MJ, Singh DC, Stover CK. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J Bacteriol. 1996;178:1274–82.
12. Harboe M, Oettinger T, Wiker HG, Rosenkranz I, Andersen P. Evidence for occurrence of the ESAT-6 protein in Mycobacterium tuberculosis and virulent Mycobacterium bovis and for its absence in Mycobacterium bovis BCG. Infect Immun. 1996;64:16–22.
13. Kobashi Y, Obase Y, Fukushima M, Yoshida K, Miyashita N, Oka M. Clinical reevaluation of the QuantIFERON TB-2G test as a diagnostic method for differentiating active tuberculosis from nontuberculous mycobacteriosis. Clin Infect Dis. 2006;43:1540–6.
14. Kuznetcova TL, Sauty A, Herbert CP. Uveitis with occult chorioditis due to Mycobacterium kansasi: limitations of interferon-gamma release assay (IGRA) tests (case report and mini-review on ocular nontuberculous mycobacteriosis and IGRA cross-reactivity). Int Ophthalmol. 2012;32:499–506.